At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ETNB 89Bio, Inc.
Halted 10-29 16:00:00 EDT
14.84
+0.00
0.00%
High14.84Low14.84Vol0.00
Open14.84D1 Closing14.84Amplitude0.00%
Mkt Cap2.20BTradable Cap1.54BTotal Shares148.31M
T/O825.47MT/O Rate0.00%Tradable Shares103.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cantor Fitzgerald Remains a Buy on 89bio (ETNB)
TIPRANKS  ·  10-31
Cantor Fitzgerald Remains a Buy on 89bio (ETNB)
89Bio to Delist Shares from Nasdaq and Terminate SEC Registration
Reuters  ·  10-30
89Bio to Delist Shares from Nasdaq and Terminate SEC Registration
Swiss stocks - Factors to watch on October 30
Reuters  ·  10-30
Swiss stocks - Factors to watch on October 30
Roche Purchases Shares In Tender Offer For 89Bio, Inc
Reuters  ·  10-30
Roche Purchases Shares In Tender Offer For 89Bio, Inc
Roche Completes Acquisition of 89bio After Successful Tender Offer
Reuters  ·  10-30
Roche Completes Acquisition of 89bio After Successful Tender Offer
13D Filings -- Barrons.com
Dow Jones  ·  10-11
13D Filings -- Barrons.com
Swiss stocks - Factors to watch on October 2
Reuters  ·  10-02
Swiss stocks - Factors to watch on October 2
Roche Launches Tender Offer to Acquire 89bio for $14.50 Per Share Plus Potential $6.00 CVR
Reuters  ·  10-02
Roche Launches Tender Offer to Acquire 89bio for $14.50 Per Share Plus Potential $6.00 CVR
HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%
Reuters  ·  10-01
HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%
Roche to Acquire 89bio for Up to $3.5 Billion in Cash and Milestone Payments
Reuters  ·  09-25
Roche to Acquire 89bio for Up to $3.5 Billion in Cash and Milestone Payments
RBC Capital Reaffirms Their Hold Rating on 89bio (ETNB)
TIPRANKS  ·  09-20
RBC Capital Reaffirms Their Hold Rating on 89bio (ETNB)
89bio Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones  ·  09-19
89bio Cut to Neutral From Buy by HC Wainwright & Co.
89Bio Inc : Raymond James Cuts to Market Perform From Strong Buy
THOMSON REUTERS  ·  09-19
89Bio Inc : Raymond James Cuts to Market Perform From Strong Buy
HC Wainwright Downgrades 89bio to Neutral From Buy, Adjusts Price Target to $14.50 From $32
MT Newswires Live  ·  09-19
HC Wainwright Downgrades 89bio to Neutral From Buy, Adjusts Price Target to $14.50 From $32
89Bio Inc : H.c. Wainwright Cuts to Neutral Rating
THOMSON REUTERS  ·  09-19
89Bio Inc : H.c. Wainwright Cuts to Neutral Rating
89bio downgraded to Neutral from Buy at H.C. Wainwright
TIPRANKS  ·  09-19
89bio downgraded to Neutral from Buy at H.C. Wainwright
89bio downgraded to Peer Perform from Outperform at Wolfe Research
TIPRANKS  ·  09-19
89bio downgraded to Peer Perform from Outperform at Wolfe Research
Gold Falls Over 1%; Darden Posts Downbeat Earnings
Benzinga  ·  09-19
Gold Falls Over 1%; Darden Posts Downbeat Earnings
89Bio Inc : RBC Raises Target Price to $15 From $11
THOMSON REUTERS  ·  09-18
89Bio Inc : RBC Raises Target Price to $15 From $11
89bio Up Over 85%, on Pace for Record Percent Increase -- Data Talk
Dow Jones  ·  09-18
89bio Up Over 85%, on Pace for Record Percent Increase -- Data Talk

Introduction

Company Name.
89Bio, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Issue price:
--